NO329145B1 - Inkorporering av aktive substanser i baerermatriser - Google Patents
Inkorporering av aktive substanser i baerermatriser Download PDFInfo
- Publication number
- NO329145B1 NO329145B1 NO20005150A NO20005150A NO329145B1 NO 329145 B1 NO329145 B1 NO 329145B1 NO 20005150 A NO20005150 A NO 20005150A NO 20005150 A NO20005150 A NO 20005150A NO 329145 B1 NO329145 B1 NO 329145B1
- Authority
- NO
- Norway
- Prior art keywords
- aqueous phase
- active substance
- emulsion
- carrier
- emulsifier
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims description 53
- 238000010348 incorporation Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims description 85
- 239000008346 aqueous phase Substances 0.000 claims description 44
- 239000012530 fluid Substances 0.000 claims description 36
- 239000000839 emulsion Substances 0.000 claims description 33
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- -1 poly(sebacic acid) Polymers 0.000 claims description 26
- 239000003995 emulsifying agent Substances 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 18
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 16
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 16
- 239000012296 anti-solvent Substances 0.000 claims description 16
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 11
- 239000012071 phase Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 9
- 239000001569 carbon dioxide Substances 0.000 claims description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 8
- 239000006185 dispersion Substances 0.000 claims description 7
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 6
- 239000004907 Macro-emulsion Substances 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 239000004530 micro-emulsion Substances 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 229920000896 Ethulose Polymers 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920002732 Polyanhydride Polymers 0.000 claims description 4
- 238000001056 aerosol solvent extraction system Methods 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 229920000570 polyether Polymers 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 241000589989 Helicobacter Species 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 239000003945 anionic surfactant Substances 0.000 claims description 2
- 239000003093 cationic surfactant Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 229920000070 poly-3-hydroxybutyrate Polymers 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 229920002643 polyglutamic acid Polymers 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 239000002888 zwitterionic surfactant Substances 0.000 claims description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- 241000590002 Helicobacter pylori Species 0.000 claims 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- 239000004721 Polyphenylene oxide Substances 0.000 claims 2
- 229940037467 helicobacter pylori Drugs 0.000 claims 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 125000003473 lipid group Chemical group 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 238000002466 solution-enhanced dispersion by supercritical fluid Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000007789 gas Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000265 homogenisation Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000003846 Carbonic anhydrases Human genes 0.000 description 5
- 108090000209 Carbonic anhydrases Proteins 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012876 carrier material Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 238000000278 gas antisolvent technique Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001046 rapid expansion of supercritical solution Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000000935 solvent evaporation Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- 238000012695 Interfacial polymerization Methods 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003889 chemical engineering Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012943 hotmelt Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229910018503 SF6 Inorganic materials 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- AFYPFACVUDMOHA-UHFFFAOYSA-N chlorotrifluoromethane Chemical compound FC(F)(F)Cl AFYPFACVUDMOHA-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000011162 core material Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- SDIXRDNYIMOKSG-UHFFFAOYSA-L disodium methyl arsenate Chemical compound [Na+].[Na+].C[As]([O-])([O-])=O SDIXRDNYIMOKSG-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 235000010958 polyglycerol polyricinoleate Nutrition 0.000 description 1
- 239000003996 polyglycerol polyricinoleate Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 1
- 229960000909 sulfur hexafluoride Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/04—Solvent extraction of solutions which are liquid
- B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
- B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
- Y10T428/2985—Solid-walled microcapsule from synthetic polymer
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- General Preparation And Processing Of Foods (AREA)
- Nozzles (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9801287A SE9801287D0 (sv) | 1998-04-14 | 1998-04-14 | Incorporation of active substances in carrier matrixes |
| PCT/SE1999/000583 WO1999052507A1 (en) | 1998-04-14 | 1999-04-09 | Incorporation of active substances in carrier matrixes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20005150D0 NO20005150D0 (no) | 2000-10-13 |
| NO20005150L NO20005150L (no) | 2000-12-08 |
| NO329145B1 true NO329145B1 (no) | 2010-08-30 |
Family
ID=20410946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005150A NO329145B1 (no) | 1998-04-14 | 2000-10-13 | Inkorporering av aktive substanser i baerermatriser |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6372260B1 (xx) |
| EP (1) | EP1069890B1 (xx) |
| JP (1) | JP2002511400A (xx) |
| KR (1) | KR100600691B1 (xx) |
| CN (1) | CN1201728C (xx) |
| AR (1) | AR019262A1 (xx) |
| AT (1) | ATE329580T1 (xx) |
| AU (1) | AU744874B2 (xx) |
| BR (1) | BR9909636A (xx) |
| CA (1) | CA2327522C (xx) |
| CY (1) | CY1105154T1 (xx) |
| CZ (1) | CZ20003784A3 (xx) |
| DE (1) | DE69931904T2 (xx) |
| DK (1) | DK1069890T3 (xx) |
| EE (1) | EE200000595A (xx) |
| ES (1) | ES2267268T3 (xx) |
| HU (1) | HUP0102305A3 (xx) |
| ID (1) | ID29286A (xx) |
| IL (1) | IL138635A0 (xx) |
| IS (1) | IS5656A (xx) |
| NO (1) | NO329145B1 (xx) |
| NZ (1) | NZ507190A (xx) |
| PL (1) | PL344077A1 (xx) |
| PT (1) | PT1069890E (xx) |
| RU (1) | RU2208435C2 (xx) |
| SE (1) | SE9801287D0 (xx) |
| SK (1) | SK14112000A3 (xx) |
| TR (1) | TR200002960T2 (xx) |
| TW (1) | TW542724B (xx) |
| WO (1) | WO1999052507A1 (xx) |
| ZA (1) | ZA992549B (xx) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6761909B1 (en) * | 1999-12-21 | 2004-07-13 | Rxkinetix, Inc. | Particulate insulin-containing products and method of manufacture |
| WO2001045731A1 (en) * | 1999-12-21 | 2001-06-28 | Rxkinetix, Inc. | Particulate drug-containing products and method of manufacture |
| GB0102075D0 (en) * | 2001-01-26 | 2001-03-14 | Astrazeneca Ab | Process |
| FR2824754B1 (fr) * | 2001-05-15 | 2004-05-28 | Separex Sa | Procede d'obtention de particules solides a partir d'au moins un produit hydrosoluble |
| GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
| US20070098784A1 (en) | 2001-09-28 | 2007-05-03 | Nutraceutix, Inc. | Delivery system for biological component |
| KR100979877B1 (ko) * | 2001-09-28 | 2010-09-02 | 뉴트라슈틱스 인코포레이티드 | 생물학적 성분의 전달 시스템 |
| US20050048077A1 (en) * | 2002-02-21 | 2005-03-03 | George Sachs | Compositions, test kits and methods for detecting helicobacter pylori |
| US6998051B2 (en) * | 2002-07-03 | 2006-02-14 | Ferro Corporation | Particles from supercritical fluid extraction of emulsion |
| GB0216780D0 (en) * | 2002-07-19 | 2002-08-28 | Bradford Particle Design Ltd | Methods of particle formation |
| US6966990B2 (en) | 2002-10-11 | 2005-11-22 | Ferro Corporation | Composite particles and method for preparing |
| US6931888B2 (en) | 2003-02-07 | 2005-08-23 | Ferro Corporation | Lyophilization method and apparatus for producing particles |
| US7083748B2 (en) * | 2003-02-07 | 2006-08-01 | Ferro Corporation | Method and apparatus for continuous particle production using supercritical fluid |
| US7455797B2 (en) * | 2003-02-28 | 2008-11-25 | Ferro Corporation | Method and apparatus for producing particles using supercritical fluid |
| CA2523883C (en) * | 2003-04-29 | 2012-01-03 | Akzo Nobel N.V. | Antisolvent solidification process |
| CA2524773C (en) | 2003-05-08 | 2014-04-08 | Nektar Therapeutics Uk Ltd | Particulate coformulations of active substances with excipients |
| US20060008531A1 (en) * | 2003-05-08 | 2006-01-12 | Ferro Corporation | Method for producing solid-lipid composite drug particles |
| WO2005022603A2 (en) * | 2003-09-02 | 2005-03-10 | Integral Technologies, Inc. | Low cost conductive containers manufactured from conductive loaded resin-based materials |
| GB0602637D0 (en) * | 2006-02-09 | 2006-03-22 | Glaxo Group Ltd | Novel process |
| NL1031224C2 (nl) * | 2006-02-23 | 2007-09-03 | Friesland Brands Bv | Het bereiden van gedroogde deeltjes met behulp van een superkritisch medium. |
| WO2007133750A2 (en) * | 2006-05-12 | 2007-11-22 | The Board Of Trustees Of The Leland Stanford Junior University | Encapsulated nanoparticles for drug delivery |
| FR2900845B1 (fr) * | 2006-05-15 | 2009-03-06 | Commissariat Energie Atomique | Procede et dispositif de synthese de particules organiques ou inorganiques enrobees |
| EP1913955A1 (en) | 2006-10-19 | 2008-04-23 | Gerhard, Markus | Novel method for treating H.pylori infections |
| US20080260852A1 (en) * | 2007-01-23 | 2008-10-23 | Ferro Pfanstiehl Laboratories, Inc. | Supercritical fluid extraction produced by in-line homogenization |
| US7745566B2 (en) * | 2007-01-23 | 2010-06-29 | Ferro Corporation | Methods for the purification of polymers |
| WO2008097664A1 (en) | 2007-02-11 | 2008-08-14 | Map Pharmaceuticals, Inc. | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
| GB0711680D0 (en) * | 2007-06-18 | 2007-07-25 | Prosonix Ltd | Process |
| EP3272354A1 (en) | 2016-07-20 | 2018-01-24 | Technische Universität München | Agents and methods for the prevention or treatment of h. pylori infections |
| KR102170146B1 (ko) * | 2019-03-05 | 2020-10-26 | 서울대학교산학협력단 | Pca 공정을 이용한 배양액의 결정화 장치 및 방법 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639441A (en) * | 1992-03-06 | 1997-06-17 | Board Of Regents Of University Of Colorado | Methods for fine particle formation |
-
1998
- 1998-04-14 SE SE9801287A patent/SE9801287D0/xx unknown
-
1999
- 1999-04-02 TW TW088105268A patent/TW542724B/zh active
- 1999-04-06 AR ARP990101561A patent/AR019262A1/es not_active Application Discontinuation
- 1999-04-06 ZA ZA9902549A patent/ZA992549B/xx unknown
- 1999-04-09 SK SK1411-2000A patent/SK14112000A3/sk unknown
- 1999-04-09 CZ CZ20003784A patent/CZ20003784A3/cs unknown
- 1999-04-09 EP EP99924076A patent/EP1069890B1/en not_active Expired - Lifetime
- 1999-04-09 CN CNB998050318A patent/CN1201728C/zh not_active Expired - Fee Related
- 1999-04-09 ID IDW20001991A patent/ID29286A/id unknown
- 1999-04-09 EE EEP200000595A patent/EE200000595A/xx unknown
- 1999-04-09 BR BR9909636-6A patent/BR9909636A/pt active Search and Examination
- 1999-04-09 PT PT99924076T patent/PT1069890E/pt unknown
- 1999-04-09 PL PL99344077A patent/PL344077A1/xx unknown
- 1999-04-09 CA CA002327522A patent/CA2327522C/en not_active Expired - Fee Related
- 1999-04-09 DE DE69931904T patent/DE69931904T2/de not_active Expired - Lifetime
- 1999-04-09 WO PCT/SE1999/000583 patent/WO1999052507A1/en active IP Right Grant
- 1999-04-09 IL IL13863599A patent/IL138635A0/xx not_active IP Right Cessation
- 1999-04-09 AT AT99924076T patent/ATE329580T1/de not_active IP Right Cessation
- 1999-04-09 RU RU2000125873/14A patent/RU2208435C2/ru not_active IP Right Cessation
- 1999-04-09 JP JP2000543117A patent/JP2002511400A/ja active Pending
- 1999-04-09 HU HU0102305A patent/HUP0102305A3/hu unknown
- 1999-04-09 KR KR1020007011361A patent/KR100600691B1/ko not_active IP Right Cessation
- 1999-04-09 NZ NZ507190A patent/NZ507190A/en unknown
- 1999-04-09 DK DK99924076T patent/DK1069890T3/da active
- 1999-04-09 ES ES99924076T patent/ES2267268T3/es not_active Expired - Lifetime
- 1999-04-09 US US09/297,440 patent/US6372260B1/en not_active Expired - Fee Related
- 1999-04-09 TR TR2000/02960T patent/TR200002960T2/xx unknown
- 1999-04-09 AU AU40663/99A patent/AU744874B2/en not_active Ceased
-
2000
- 2000-10-11 IS IS5656A patent/IS5656A/is unknown
- 2000-10-13 NO NO20005150A patent/NO329145B1/no not_active IP Right Cessation
-
2006
- 2006-08-11 CY CY20061101138T patent/CY1105154T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO329145B1 (no) | Inkorporering av aktive substanser i baerermatriser | |
| EP1071457B1 (en) | Polymer particle vaccine delivery system | |
| US6291013B1 (en) | Emulsion-based processes for making microparticles | |
| EP1549410B1 (en) | Method for preparing composite particles | |
| US6180141B1 (en) | Composite gel microparticles as active principle carriers | |
| Patidar et al. | A review on novel lipid based nanocarriers | |
| NO310177B1 (no) | Fremgangsmåte for å innkapsle en aktiv substans samt vedvarende frigivelsesmikro- eller nanopartikler | |
| EP1499296B1 (en) | Formulation of fine particles using liquefied or dense gases | |
| US7901606B2 (en) | Production of porous materials by supercritical fluid processing | |
| JP2007518780A (ja) | マイクロ粒子の製造方法 | |
| MXPA00009914A (en) | Incorporation of active substances in carrier matrixes | |
| Yoo | The development of biodegradable microspheres for sustained release of proteins using a stable polymer aqueous-aqueous emulsion technology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |